Prostacare

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Prostacare

Property Description
Active ingredient Finasteride
Form Oral film-coated tablet
Pharmacological class 5-alpha Reductase Inhibitor
General purpose Mitigate conditions driven by DHT
Origin Synthetic steroid analog

What Type of Medicine is Prostacare (Finasteride)?

Prostacare is a prescription drug defined by its active ingredient, Finasteride, a synthetic compound with a distinct steroidal structure. The drug is consistently classified within the pharmacological class of 5-alpha Reductase Inhibitors (5ARIs). This classification is clinically recognized for its specific mechanism in managing hormonal factors in adult men. As a monotherapy, Prostacare is prepared as an oral film-coated tablet, a dosage form intended for systemic action following oral administration.


How Does Prostacare Work at a Fundamental Level?

The fundamental principle of Prostacare’s action is the competitive and specific inhibition of 5-alpha Reductase, which is an intracellular enzyme. By selectively blocking this enzyme, the medicine impedes the conversion of the androgen Testosterone into the more potent androgen, Dihydrotestosterone (DHT). The resulting reduction in DHT levels helps to mitigate the adverse effects that this hormone has on specific cells in the body. The general purpose of this action is to stabilize and potentially slow the progression of various androgen-dependent conditions that rely on the presence of high Dihydrotestosterone concentrations in sensitive tissues.


Finasteride: Composition, Form, and Analogue Distinction

The medicine’s composition consists solely of the active ingredient Finasteride along with the necessary solid excipients that form the tablet core and film coating, confirming it as a single active ingredient product. This composition and specific steroidal structure define its unique characteristics. Although other compounds, such as Dutasteride, share the classification of 5-alpha Reductase Inhibitors, Finasteride is known to exhibit a preferential selectivity for the Type II isoenzyme of the 5-alpha reductase enzyme, distinguishing its molecular target within the class. Finasteride’s mechanism is to inhibit the conversion of testosterone to Dihydrotestosterone, establishing the role of the medication in the therapeutic landscape.

What side effects are possible with Prostacare?

Possible Side Effects and Safety Information

Prostacare (finasteride) is associated with several categories of adverse reactions documented in regulatory sources, primarily impacting sexual function and hormonal systems, with specific safety warnings for certain populations.

Common and Serious Adverse Reactions

The most frequently reported adverse reactions include impotence (trouble getting or keeping an erection), decreased libido (sex drive), decreased volume of ejaculate, breast enlargement (gynecomastia), breast tenderness, and rash.

Serious adverse reactions reported in clinical data and postmarketing surveillance include:

  • Increased risk of high-grade prostate cancer (a more serious form of the disease).
  • Persistent sexual side effects (erectile dysfunction, decreased libido, ejaculation disorders) that may continue after stopping the medication.
  • Psychiatric effects such as depression and, in rare instances, suicidal thoughts have been reported.
  • Hypersensitivity reactions, including swelling of the lips, tongue, throat, and face (angioedema), which require immediate medical attention.
  • Male breast cancer has been reported in rare postmarketing instances.

Safety Considerations and Restrictions

  • Pregnancy Risk: Females who are, or may potentially be, pregnant must not handle crushed or broken tablets due to the risk of absorption. The active ingredient can cause abnormalities of the external genitalia in a developing male fetus. The drug is not indicated for use in women or pediatric patients.
  • PSA Monitoring: Prostacare significantly decreases serum Prostate Specific Antigen (PSA) levels. This necessitates that any confirmed rise in PSA from its lowest point must be carefully evaluated by a healthcare provider for the possible presence of prostate cancer, even if the value appears within the normal range for men not taking the medication.
  • Hepatic Impairment: Caution is generally advised in patients with liver function abnormalities, as the drug is extensively metabolized by the liver.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents on Prostacare (Finasteride) establish a specific profile regarding acute exposure. Clinical studies documented in official prescribing information show that single doses of the active ingredient up to 400 mg and multiple daily doses up to 80 mg for three months did not result in documented dose-related side effects or adverse reactions.

Feature Regulatory Documentation Status
Documented Manifestations No specific signs or symptoms are formally described as acutely arising from Finasteride overexposure.
Antidote Availability No specific treatment of overdose with Finasteride is recommended in official labeling, indicating that no specific antidote is known.

Given the findings of low acute toxicity, management is considered supportive and symptomatic. The regulatory focus shifts to immediate action protocols. In the event of any suspected overdose, official guidance mandates immediately contacting a regional poison control centre for professional management advice. Emergency medical help, which requires calling emergency services, is necessitated if severe systemic events are observed, such as the victim collapsing, experiencing a seizure, having trouble breathing, or being unable to be awakened. These severe symptoms are the established triggers for immediate, urgent medical intervention.

Therapeutic Uses of Prostacare

What Prostacare Treats: Main Uses and Benefits

Prostacare is therapeutically relevant across two distinct domains, offering targeted support for managing specific symptoms and managing the course of conditions characterized by long-term, specific physiological activity in adult men. This medication is commonly used for two main indications: Benign Prostatic Hyperplasia (BPH) and Androgenetic Alopecia (male pattern hair loss).


Addressing Symptoms and Progression

This medicine is commonly used to treat the chronic symptoms of BPH, such as frequent and difficult urination, weak urinary stream, and nighttime awakenings (nocturia). In conditions involving an enlarged prostate, this therapy provides support that helps ease the overall symptom burden and may assist with reducing the potential for significant functional strain associated with this condition.

In the context of hair loss, Prostacare is applied where it is relevant for easing the progressive and gradual thinning of hair. It is generally considered relevant for the stabilization of the hairline and increasing hair density on the scalp, primarily in the vertex area. This benefit contributes to improved comfort by playing a role in managing further hair loss, which helps maintain a sense of stability when symptoms are more noticeable.


Quick Fact: Relief for Urinary and Hair Symptoms
Common Clinical Scenario Applied in chronic conditions to manage bothersome urinary symptoms and manage the effects of progressive hair thinning.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Prostacare (Finasteride)

Eligibility Scope Official Regulatory Status
Populations Allowed Adult men, 18 years of age and older.
Contraindicated Groups Women (especially when pregnant or potentially pregnant); Patients with known hypersensitivity to any component; Men concurrently using another 5-alpha reductase inhibitor.

Age-Related Eligibility Rules

The medicine is not indicated for use in pediatric patients (under 18 years), as safety and effectiveness have not been established in this age group. Use is permitted in geriatric patients (older adults) with no dosage adjustment necessary, as regulatory data indicates a lack of geriatric-specific problems.

Condition and Physiological State Restrictions

The medicine is contraindicated in women who are or may be pregnant due to the potential risk of abnormal development of a male fetus. Pregnant women must not handle crushed or broken tablets. For patients with renal impairment (kidney disease), no dosage adjustment is required. However, caution is advised when administering the medicine to patients with hepatic insufficiency (liver function abnormalities), as the drug is metabolized extensively in the liver.

Connection to the overall eligibility profile

Regulatory documents strictly define the eligible population as adult men. This profile imposes absolute non-eligibility based on sex, reproductive status, and hypersensitivity, and establishes conditional use based on organ function, ensuring eligibility is limited only to criteria mandated by health authorities.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines interactions with other medicinal products as defined in official government regulatory documents.

The regulatory profile for this product indicates that no formal interaction studies have been performed.

Pharmacodynamic Risk

The most significant interaction consideration is a pharmacodynamic risk associated with the primary treatment class. Androgen deprivation treatment may affect the heart's electrical activity by prolonging the QT interval.

Interacting Medicines and Required Evaluation

Co-administration with medicines that also prolong the QT interval or are associated with a specific type of abnormal heart rhythm called Torsade de pointes must be carefully evaluated by a healthcare professional. This is due to the potential for an additive effect on the heart's electrical system.

Examples of interacting medicines requiring careful evaluation include:

Category
Class IA Antiarrhythmics (e.g., quinidine, disopyramide)
Class III Antiarrhythmics (e.g., amiodarone, sotalol, dofetilide, ibutilide)

Other Interactions

For specific populations, official documents note that no known interactions exist for women and girls. The regulatory focus remains exclusively on the potential combined cardiac risk with the listed antiarrhythmic agents.

Mechanism of Action

Targeted Enzyme Inhibition: 5-alpha Reductase

Prostacare is a specific inhibitor that acts by forming a stable, non-functional complex with the intracellular enzyme 5-alpha Reductase (5AR) Type II. This enzyme is the primary biological target, responsible for the conversion of the androgen Testosterone into the active androgen, Dihydrotestosterone (DHT). Engaging this mechanism is relevant in systems where targeted pathway adjustment of steroid metabolism is required.

Modulating Androgen-Driven Cell Signaling

The inhibition of 5AR Type II initiates a cascade that results in a measurable, sustained reduction in local and systemic DHT concentration. By lowering the availability of this androgen, the drug modifies early molecular steps that regulate cell activity in sensitive tissues. The resulting reduction in DHT availability modulates the excessive proliferative signaling within targeted pathways.

Mechanistic Selectivity and Pathway Limits

The drug's mechanism exhibits high selectivity for the Type II isoenzyme, which is prominent in the prostate and hair follicles, but has a weaker effect on the Type I isoenzyme. This difference in activity patterns means the synthesis of DHT is substantially suppressed, yet not completely eliminated, allowing a residual level of androgenic activity to persist in the body.

Dosage and Administration Information

How to Use Prostacare (Finasteride)

Prostacare is a prescription medication administered orally as a film-coated tablet for systemic action. Official usage instructions specify distinct daily doses corresponding to the clinical scenario. For the management of Benign Prostatic Hyperplasia (BPH), the standard labeled dose is 5 milligrams (mg) taken once daily. For the stabilization of Androgenetic Alopecia (male pattern hair loss), the dose is 1 mg taken once daily.

Administration Rules and Consistency

The established frequency for the medication is once daily, a schedule intended for consistent, long-term use. The official labeled instructions specify that the tablet may be administered with or without food. A key procedural condition is that the film-coated tablet must be swallowed whole and is not to be crushed, broken, or divided. If a dose is missed, the standard procedure is to skip the forgotten dose and resume the regimen at the next scheduled time; a double dose should not be taken.

Usage in Specific Populations

Dosing rules state that no routine dosage adjustment is required for older adult patients. Similarly, no modification to the standard dose is necessary for patients with any degree of renal impairment. Clinical evaluation of the treatment course for both BPH and Androgenetic Alopecia requires an extended period of consistent administration, typically three to six months, before therapeutic status can be properly assessed.

Recent Clinical Evidence

Prostacare: Recent Clinical Evidence

The research base includes clinical studies, such as randomized controlled trials (RCTs) and meta-analyses, which have explored Prostacare's evaluation concerning changes in urinary symptoms and observed BPH features.

Evidence for Use in Benign Prostatic Hyperplasia (BPH)

Research has explored the use of Prostacare in the context of conditions characterized by fluctuating manifestations of BPH. Large-scale, controlled clinical trials examined outcomes related to systemic or functional imbalance in adult men with noticeable symptoms. The findings derived from these settings focused on patterns observed during the study periods, including data related to changes in prostate size and the documentation of specific clinical and surgical outcomes. Reports detailed measurements of standardized urinary symptom scores in the enrolled patients, with long-term studies detailing measurements collected over periods up to five years or more. However, long-term effects beyond these periods are not fully established.

Evidence for Use in Androgenetic Alopecia (Male Pattern Hair Loss)

The research base also includes clinical trials and long-term observational reports that have explored outcomes related to hair count, density, and observed patterns of progressive hair thinning. These studies were primarily conducted using controlled trial designs over periods of one to two years, focusing on adult men with mild-to-moderate thinning. Research reported that measured hair counts in the study groups evolved differently compared to control groups. Findings also described patterns related to the progression of hair loss, based on assessments from investigators and patients. Data for certain groups, such as men with severe hair loss or specific areas like the frontal hairline, appear limited.

Research Gaps and Uncertainties

Evidence related to some less-frequently monitored outcomes appears limited, and study results reflect the specific conditions under which they were conducted. Comparative evidence against all other treatment types is sometimes lacking. Furthermore, data for certain subgroups—such as older adults with complex medical conditions—appear limited, and research is ongoing to better characterize these long-term outcomes.

Key Studies & References

  1. Finasteride: Drug Information (NIH MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Prostacare (FAQ)


Q: How long does it usually take to notice an effect from Prostacare?

A: Regulatory information indicates that consistent daily use for three months or more is typically required before a potential benefit may be assessed. To maintain any observed effect, continued use is described as necessary, and if the medication is stopped, the effects typically reverse within one year.

Q: Does Prostacare cure the condition it treats?

A: Regulatory documents state that Prostacare is authorized for the treatment and control of benign prostatic hyperplasia (BPH) and the stabilization of male pattern hair loss. If treatment is discontinued, the symptoms or condition is generally expected to return. Official documentation does not describe the medicine as a cure.

Q: Does Prostacare affect sexual function?

A: Official reports and safety warnings confirm that the medicine is associated with adverse effects on sexual function. These include decreased sex drive (libido), trouble getting or keeping an erection (impotence), and decreased ejaculatory volume. Health authorities also warn that these effects may persist after stopping the medication in some individuals.

Q: Does Prostacare interact with common over-the-counter pain relievers?

A: Formal interaction studies for common over-the-counter (OTC) pain relievers have not been performed, according to regulatory documents. Official patient information from some health authorities generally suggests that a significant interaction with standard, non-prescription pain relievers has not been a key focus of formal studies.

Q: What do clinical studies say about the long-term use of Prostacare?

A: Clinical trials and long-term observational studies have evaluated the medication for periods up to several years. Regulatory information notes that the frequency of new reports of drug-related sexual adverse experiences decreased with the duration of therapy. However, the relationship between very long-term use and some rare outcomes remains a subject of ongoing evaluation.

Q: Does Prostacare affect blood pressure?

A: Official data and postmarketing surveillance have included reports of effects related to blood pressure. These observed adverse reactions include low blood pressure (hypotension) and postural hypotension, which is a drop in blood pressure that can occur when a person moves from a seated or lying position to standing.

Q: Can I stop taking Prostacare suddenly?

A: Official regulatory guidance emphasizes that when treatment is stopped, the symptoms of the condition are generally expected to return. The beneficial effects on the treated condition are generally expected to gradually reverse within about a year.

Q: Does taking Prostacare affect male fertility?

A: Postmarketing reports received by health authorities have included observations of male infertility and poor seminal quality in some patients. In certain cases, the quality of sperm has been reported to return toward normal after the medicine was stopped.

Q: Does Prostacare affect cholesterol levels?

A: While the drug's mechanism involves steroid-related pathways, a change in overall cholesterol levels is not specifically listed as a documented adverse reaction in the key official prescribing documents.

Q: What is the chance of experiencing a rare side effect mentioned in the official documents?

A: Regulatory documents classify side effects using standard frequency terms like 'Common,' 'Uncommon,' or 'Very Rare,' based on clinical trial data. For effects reported only after the medicine was marketed, the frequency is often listed as 'Incidence not known' because the exact chance of occurrence cannot be reliably estimated from available reports.

Q: Can the effectiveness of Prostacare decrease over time?

A: Official documents do not specifically describe a loss of effectiveness or tolerance over time. Regulatory guidance describes the drug's intended use as consistent, long-term administration to sustain potential benefit, and the patient's status should be re-evaluated on a regular basis.

Q: Is there a known interaction between Prostacare and alcohol?

A: Official patient information from health authorities states that there is generally no known interaction with alcohol. The primary regulatory focus for drug interactions is on specific heart medications (Class IA/III Antiarrhythmics).

Q: Is Prostacare safe for people with kidney problems?

A: Official prescribing information indicates that no change or adjustment to the standard dose is necessary for patients who have any degree of renal (kidney) impairment.

Q: Can Prostacare be taken with common heartburn or stomach medicines?

A: No formal interaction studies have been conducted with common stomach or heartburn medicines. Official patient advice generally suggests that a significant interaction with common heartburn or stomach medicines has not been a key focus of formal studies.

Q: Can I take Prostacare if I am also taking medication for diabetes?

A: Regulatory documents indicate that no formal interaction studies have been performed with most other medicines. Official patient information from some health authorities generally suggests that a significant interaction with common prescription medicines, such as those for diabetes, has not been a key focus of formal studies.

Q: Is it normal to feel tired after starting Prostacare?

A: The official list of adverse reactions includes somnolence (unusual drowsiness or sleepiness) as an effect that has been reported. This may be related to general feelings of tiredness in some users.

Q: What is the difference between Prostacare and Tamsulosin?

A: Prostacare is a 5-alpha reductase inhibitor that works by lowering the level of the hormone DHT. Tamsulosin belongs to a separate class of medicines called alpha-blockers, which work by relaxing muscles in the prostate and bladder. They use different pharmacological mechanisms to address the condition.

Q: How is Prostacare different from herbal supplements for prostate health?

A: Prostacare is a prescription-only medicine that has been authorized by government health authorities following clinical trials. Herbal supplements are generally regulated as food or dietary supplements and are not required to meet the same authorization standards as prescription medicines.

Q: Can Prostacare cause weight gain?

A: While not listed as a common side effect, official sources have occasionally included reports of unusual weight changes, such as rapid weight gain, or edema (swelling), as less common or postmarketing adverse reactions.

Q: Are there any food restrictions when taking Prostacare?

A: No. Official administration rules are clear that the tablet may be administered with or without food. There are no specific food restrictions mentioned in regulatory documents.

Q: Is it okay to take Prostacare with vitamins or supplements?

A: Formal studies on the interaction between this medicine and most vitamins or dietary supplements have not been conducted. Regulatory documents indicate that supplements are generally not required to undergo testing for their potential effect on the pharmacokinetics of prescription medicines.

Q: Is it true that Prostacare might be associated with changes in mood?

A: Yes. Official safety warnings and postmarketing reports have noted associations with depressed mood, depression, and, in rare instances, suicidal thoughts. Health authorities advise that patients should be monitored for psychiatric side effects.

Q: Does Prostacare contain gluten or lactose?

A: The official list of ingredients (excipients) confirms that the tablets contain lactose monohydrate. The medicine is generally considered free of gluten, though it is advised to check the full list of excipients if there are specific concerns.

Q: Does the time of day I take Prostacare matter?

A: Official advice states that it does not matter what time of day the medicine is taken. However, for consistent therapeutic effect, it should be taken once daily, preferably around the same time each day.

Q: Are there any official warnings about taking Prostacare before surgery?

A: There is no general warning against all surgeries. The regulatory label does warn about a pharmacodynamic risk related to the heart’s electrical activity (the QT interval) and requires careful evaluation if taken with specific heart medicines before or during surgical procedures.

Q: Can Prostacare affect my ability to drive or operate machinery?

A: Official patient information often states that Prostacare is not likely to affect the ability to drive, use tools, or operate machinery. However, any reported effects like dizziness or sleepiness should be considered.

Q: How is the interaction with herbal supplements classified in official documents?

A: Official regulatory documents generally note that no formal interaction studies have been performed involving herbal remedies or supplements. Some official patient advice mentions that certain herbal remedies, like St. John’s Wort, may potentially affect how the medicine works.

Q: What is the recommended duration of treatment with Prostacare?

A: The medicine is designated for consistent, long-term use. Patients are generally advised that they may need to continue taking it for several months or years, and the need for ongoing therapy should be reviewed periodically.

Q: Are there different forms of Prostacare available (e.g., tablet, capsule)?

A: Official documentation lists Prostacare as an oral film-coated tablet. Other dosage forms, such as capsules or liquid solutions, are not listed in the official prescribing information.

How should Prostacare be stored and disposed of?

How to Store and Dispose of Prostacare (Finasteride)

Prostacare must be stored according to specific regulatory requirements to maintain product stability and ensure household safety.


Official Storage Conditions

Requirement Specification
Temperature Store at room temperature, typically 15 C to 30 C (59 F to 86 F).
Protection Keep in a dry place, protected from light, and keep from freezing.
Packaging Must remain in the original, closed container.

Handling and Disposal

Child Safety: The medication must be kept out of the sight and reach of children.

Special Handling: Pregnant women must not handle crushed or broken tablets due to the risk of absorption.

Disposal: Do not throw away unused or expired tablets in household waste or flush them down the toilet. Consult a pharmacist for authorized disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Prostacare found in:

A-Z Index: